ARIAD Pharmaceuticals Inc
Most Recent
Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17
In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.
What Sprycel Could Mean for Bristol-Myers Squibb
In 2016, Bristol-Myer Squibb’s (BMY) Sprycel reported revenues of ~$1.8 billion, which represents a ~13% YoY rise.
Who Is Incyte Collaborating With?
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.
Understanding Incyte’s Revenue Stream for 2016
Incyte’s business revenues are reported under three segments: product, royalty, and contract.
Why These Collaborations Are Important to Incyte
Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.
What’s in Incyte’s Product Portfolio?
Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.
How Ionis Pharmaceuticals’ Valuation Compares to Its Peers
Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.
These Collaborations Could Boost Jakafi Sales
Incyte’s (INCY) collaborations and developments include its acquisition of Ariad Pharmaceuticals’ (ARIA) European operations in June 2016.
Incyte’s Profitability Improves, Allowing for Revised Guidance
Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.
Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.
Understanding Incyte’s Revenue Stream in 2Q16
Incyte (INCY) reported revenues of $246.3 million in its 2Q16 results. This converts to a 51% revenue growth in 2Q16 compared to $163 million in 2Q15.
Is Incyte Hurt by Having Only One FDA-Approved Drug?
Jakafi (ruxolitinib) is Incyte’s only product and the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, rare types of blood cancer.
How Could the Novartis-Xencor Alliance Benefit Novartis?
As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.
The Details of Incyte’s Agreement with Ariad Pharmaceuticals
In May 2016, Incyte (INCY) entered into an agreement to acquire the European operations of Ariad Pharmaceuticals (ARIA). It would help Incyte expand its footprint in European markets.
Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?
Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.
IBB Falls as Energy Sector Negatively Influences the Market
The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.